Want to see OCGN full AI Analyst Report?
OCGN Stock Chart & Stats
$1.21
$0.05(4.13%)
At close: 4:00 PM EDT
$1.21
$0.05(4.13%)
Day’s Range― - ―
52-Week Range$0.99 - $2.73
Previous Close$1.26
Volume5.01M
Average Volume (3M)8.17M
Market Cap
$501.88M
Enterprise Value$506.12
Total Cash (Recent Filing)$100.05M
Total Debt (Recent Filing)$87.99M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume4,592,933
30 Day Avg. Volume8,170,514
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside747.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$4.50M
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical And Regulatory ProgressMultiple programs have advanced into registrational development, reducing early-stage risk and creating several potential approval catalysts. RMAT designation and completed OCU400 enrollment may support regulatory engagement and a more diversified path to commercialization.
Manufacturing ReadinessCompleted PPQ batches indicate progress beyond clinical efficacy toward scalable, compliant production. This can reduce a key execution barrier before launch, support regulatory filings, and improve readiness to supply commercial demand if OCU400 receives approval.
International Licensing PlatformThe MENA agreement provides a potential non-dilutive pathway to broaden OCU400 access while retaining manufacturing economics and royalties. It also validates regional partnering interest and could establish a template for additional commercialization deals.
Bears Say
Persistent Cash Burn And Financing DependenceOcugen is not self-funding and must continue relying on capital markets, partnerships, or contingent financing sources to advance its pipeline. Sustained cash use increases refinancing risk and can constrain development or commercialization flexibility if funding conditions change.
Weak Balance SheetNegative equity combined with sharply higher debt reduces financial resilience and limits balance-sheet flexibility. The structure raises refinancing and dilution risk, particularly because the company remains pre-commercial and has not demonstrated recurring product revenue.
Unproven Profitability And Rising CostsRevenue remains too small to offset research and corporate spending, while advancing three late-stage programs is increasing operating costs. Until a candidate is approved and commercially adopted, persistent losses make long-term earnings and margin sustainability unproven.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.99 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $501.88M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 10, 2026 which is in 81 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.053 by -$0.017.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 339,110,400 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.053. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (747.11% Upside)
$10.25 (747.11% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 80%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
131.75%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$10.25
▲(747.11% Upside)
Technical Analysis
Ownership Overview
2.65% Insiders
5.46% Mutual Funds
5.96% Other Institutional Investors
71.05% Public Companies and
Individual Investors